BioMimetic Therapeutics to Announce Interim U.S. Clinical Trial Results for GEM OS1;
Press Release and Conference Call Scheduled for Dec. 13
Franklin, Tenn. – December 11, 2006 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release on Wednesday, December 13, 2006 interim results for the U.S. pilot clinical trial for the use of GEM OS1 ™ Bone Graft in foot and ankle fusion indications. The Company will host a conference call and audio webcast at 5:00 p.m. EST the same day. Dr. Samuel E. Lynch, president and CEO, members of the Company's management team, and clinical investigators for BioMimetic's U.S. pilot clinical trial, will host the call to discuss the study findings followed by a Q&A session.
The conference call can be accessed by dialing 800-798-2864 (passcode 31607580) on December 13. The international dial in number is 617-614-6206. The same passcode applies. Participants should dial in 15 minutes prior to the 5:00 p.m. call. A live webcast of the conference call will be available on the Investor Relations section of BioMimetic's website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active drug-device combination products for the healing of musculoskeletal injuries and disease, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S ®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing for orthopedic bone healing indications. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of BioMimetic. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. There are many important factors that could cause actual results to differ materially from those indicated in the forward-looking statements. BioMimetic's actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with the marketing of BioMimetic's product and product candidates, unproven preclinical and clinical development activities, regulatory oversight, and other risks detailed in the company's filings with the Securities and Exchange Commission. Except as required by law, BioMimetic undertakes no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for changes made to this document by wire services or Internet services.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, manager corporate communications, at 615-236-4419.
Back to Headlines |
